CLRB
Cellectar Biosciences, Inc.Company Information
- Company Name
- Cellectar Biosciences, Inc.
- CIK
- CIK0001279704
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- CLRB: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CLRB
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-07
- Last sale
- 2025-12-12
- Shares purchased (TTM)
- 42,360
- Shares sold (TTM)
- 198
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 3,243,061
- Shares outstanding
- 12,231,851
- Ownership
- 26.51%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -4.44%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 34 | 8 | 13 | 13 | 11 | 14 | 23 | 34 | 26 | 40 | 10 | 19 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | ||||||
| Assets Current | 35 | 9 | 14 | 14 | 13 | 15 | 24 | 36 | 28 | 41 | 10 | 20 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | ||||||
| Long Term Investments | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 37 | 11 | 15 | 15 | 14 | 16 | 25 | 37 | 29 | 43 | 12 | 22 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 5 | 5 | 4 | 4 | 5 | 4 | 8 | 8 | 6 | 7 | 9 | 8 | ||||||
| Derivative Liabilities Current | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 12 | 9 | 21 | 16 | 9 | ||||||
| Operating Lease Liability Current | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Series D Preferred Stock | - | - | - | - | - | - | - | - | - | 0 | 0 | - | ||||||
| Liabilities Current | 5 | 5 | 5 | 5 | 6 | 6 | 9 | 20 | 15 | 29 | 25 | 16 | ||||||
| Operating Lease Liability Noncurrent | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Liabilities | 7 | 6 | 5 | 5 | 6 | 6 | 10 | 21 | 16 | 29 | 26 | 17 | ||||||
Temporary Equity | ||||||||||||||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | - | - | - | 1 | 1 | 18 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | 1 | - | 1 | 1 | - | - | - | - | - | - | 1 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 312 | 278 | 277 | 271 | 265 | 262 | 261 | 247 | 235 | 225 | 183 | 195 | ||||||
| Retained Earnings Accumulated Deficit | -282 | -275 | -269 | -264 | -259 | -254 | -247 | -245 | -230 | -229 | -203 | -210 | ||||||
| Stockholders Equity | 30 | 3 | 9 | 8 | 6 | 8 | 14 | 15 | 12 | 13 | -15 | -28 | ||||||
| Liabilities And Stockholders Equity | 37 | 11 | 15 | 15 | 14 | 16 | 25 | 37 | 29 | 43 | 12 | 22 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | - | 0.00 | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Temporary Equity Shares Issued | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | - | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | 0 | 0 | - | - | - | - | 0 | - | 0 | ||||||
| Preferred Stock Shares Issued | - | - | - | 0 | 0 | - | - | - | - | - | - | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | 0 | 0 | - | - | - | - | - | - | 0 | ||||||
| Series D Convertible Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 1 | - | ||||||
| Series E2 Preferred Stock | 0 | 0 | 0 | - | - | 0 | 0 | -0 | 0 | 0 | 0 | - | ||||||
| Series E3 Preferred Stock | - | - | - | - | - | - | - | 0 | -12 | 12 | - | - | ||||||
| Series E4 Preferred Stock | - | - | - | - | - | - | - | 0 | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 170 | 170 | 170 | 170 | 170 | 170 | 170 | 170 | 170 | 170 | 170 | 160 | ||||||
| Common Stock Shares Issued | 8 | 4 | 4 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 0 | ||||||
| Shares Outstanding | 8 | 4 | 4 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCellectar Biosciences, Inc. (CLRB) — SEC Financial Statements & Analysis
Cellectar Biosciences, Inc. (CLRB) is a pharmaceutical preparations company, incorporated in DE. Cellectar Biosciences, Inc. trades on Nasdaq as: CLRB. Cellectar Biosciences, Inc. (CLRB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Cellectar Biosciences, Inc. carries a market cap of $34.00M, a P/E ratio of -1.52x, a P/B ratio of 1.14x, an enterprise value of $10.56K, and an EV/EBITDA multiple of -0.00x. On profitability, it posts a Return on Equity (ROE) of -124.17% and a Return on Assets (ROA) of -88.70%. Per share, it reports EPS of $-1.83, diluted EPS of $-1.83, free cash flow per share of $-1.59, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -23.21% year-over-year and EPS growth of -89.90% year-over-year. On the balance sheet, it maintains a current ratio of 6.66x, a quick ratio of 6.49x, working capital of $29.64M, a debt-to-equity ratio of 0.23x, a debt ratio of 0.18, an interest coverage ratio of -57.89x, free cash flow of $-19.48M (TTM), and net debt of $-33.99M. Figures sourced from SEC EDGAR.
- Market Cap
- $34.00M
- P/E TTM
- -1.52x
- EPS TTM
- $-1.83
- P/B TTM
- 1.14x
- ROE TTM
- -124.17%
- ROA TTM
- -88.70%
- Debt To Equity
- 0.23x
- Free Cash Flow TTM
- $-19.48M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Cellectar Biosciences, Inc. in?
Cellectar Biosciences, Inc. (CLRB) operates in the Pharmaceutical Preparations industry.
What exchange does CLRB trade on?
Cellectar Biosciences, Inc. (CLRB) trades on the Nasdaq.
Where is Cellectar Biosciences, Inc. incorporated?
Cellectar Biosciences, Inc. is incorporated in DE.
When was Cellectar Biosciences, Inc. (CLRB)'s most recent SEC filing?
Cellectar Biosciences, Inc. (CLRB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is CLRB's market cap?
Cellectar Biosciences, Inc. (CLRB) has a market capitalization of $34.00M as of 2026-06-30.
What is CLRB's EPS (earnings per share)?
Cellectar Biosciences, Inc. (CLRB)'s trailing twelve month EPS is $-1.83 as of 2026-06-30.
What is CLRB's ROE (return on equity)?
Cellectar Biosciences, Inc. (CLRB)'s trailing twelve month Return on Equity (ROE) is -124.17% as of 2026-06-30.
What is CLRB's ROA (return on assets)?
Cellectar Biosciences, Inc. (CLRB)'s trailing twelve month Return on Assets (ROA) is -88.70% as of 2026-06-30.
What is CLRB's EV/EBITDA?
Cellectar Biosciences, Inc. (CLRB)'s trailing twelve month EV/EBITDA is -0.00x as of 2026-06-30.